

Calendar Year 2021 Supplemental Rebate Agreement Reporting

February 1, 2023



*Division of Health Care Financing & Policy
Nevada Medicaid
Nevada Department of Health and Human Services*

Joe Lombardo
Governor

Richard Whitley, MS
Director
Department of Health and Human Services

Stacie Weeks, JD, MPH
Administrator
Division of Health Care Financing and Policy

Calendar Year 2021 Supplemental Rebate Agreement Reporting

Section 6 of Nevada Revised Statutes 422.4025 requires reporting concerning the agreements negotiated and contracts entered into pursuant to NRS 422.4053 which must include, without limitation, the financial effects of obtaining prescription drugs through those agreements and contracts, in total and aggregated separately for agreements negotiated by the Department, contracts with a pharmacy benefit manager, contracts with a health maintenance organization and contracts with public and private entities from this State, the District of Columbia and other states and territories of the United States.

In Nevada, three managed care organizations and/or their pharmacy benefit managers entered into rebate agreements and contracts to purchase prescription drugs included on the list of preferred prescription drugs for health plans under the Medicaid program. A pharmacy benefit manager enters into rebate agreements on behalf of the Fee-for-Service Medicaid program. A summary of these agreements is provided in Table 1 below.

Table 1

Summary of Supplemental Rebate Agreements for Health Plans – Calendar Year 2021			
Health Plan	Number of Unique Manufacturers Under Contract	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
Anthem	183	\$5,427,189	\$5,193,555
Health Plan of Nevada	41	\$11,941,312.18	\$11,747,129.89
SilverSummit Healthplan	183	\$1,166,421	\$1,104,246
Totals for Managed Care Health Plans	-	\$18,534,922	\$18,044,931
Fee-for-Service Medicaid	32	\$10,883,847.34	\$9,116,888.34
Totals	-	\$29,418,770	\$27,161,819

Each of these managed care organizations has provided additional information specific to their health plan’s supplemental rebate agreements in the following order:

- Anthem (pages 4 - 15)
- Health Plan of Nevada (pages 16 - 22)
- SilverSummit Healthplan (pages 23 - 34)

Please note that some information was not included in Table 3 by the MCOs. Current contracts with MCOs are being reviewed to ensure compliance for future reports.

Additional information specific to supplemental rebate agreements related to prescription drugs for fee-for-service Medicaid recipients is provided by a pharmacy benefit manager vendor (OptumRx):

- Fee-for-Service Medicaid (pages 35 - 40)

Please refer to the individual reports within this document for more information.

Anthem Blue Cross and Blue Shield Healthcare Solutions
Supplemental Rebate Agreement Report
Calendar Year 2021

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid Drug Rebate Program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA's. The formulas for calculating the Federal Unit Rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter into separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists (PDL).

Generally, the SRAs are in effect for one calendar year beginning on January 1st and terminating on December 31st. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31st end date such as a product moving to non-preferred status or to coincide with planned coverage review.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- "Percentage of WAC" - set percentage of the drug's published wholesale acquisition cost (WAC).
- "GNUP" (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
 - In the event a drug's WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
 - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Anthem Blue Cross and Blue Shield Healthcare Solutions price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer's SRA with the managed care organization.

Anthem Blue Cross and Blue Shield Healthcare Solutions had 189 SRAs in place that were in effect during Calendar Year 2021 (January 1, 2021 – December 31, 2021) (hereinafter referred to as CY 2021). Table 1 below summarizes the agreements.

Table 1 Row Definitions:

- **Number of Contracts** - The count of signed SRAs that were in force during some period within CY 2021.
- **Number of Unique Manufacturers Under Contract** - The count of unique manufacturers with a signed SRA in force during some period within CY 2021.
- **Amount Plan Paid for Products During Contract Term** - The amount Anthem Blue Cross and Blue Shield Healthcare Solutions paid for all drug utilization subject to a manufacturer’s SRA during CY 2021.
 - **Example:** Drug “A” was subject to an SRA from 04/01/2021 to 12/31/2021 would include the amount paid for Drug “A” for claims paid from 04/01/2021 to 12/31/2021.
- **Amount Plan Paid to Pharmacies/Providers for Products Under Contract** – The amount Anthem Blue Cross and Blue Shield Healthcare Solutions paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2021.
- **Total Supplemental Rebates Invoiced** - The supplemental rebate amount invoiced during CY 2021 to manufacturers for drugs subject to SRAs.
- **Total Supplemental Rebates Collected** - The supplemental rebate amount collected during CY 2021 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.
 - **Example:** Manufacturer B was invoiced \$100.00 for supplemental rebates in November 2020 and remitted payment in January 2021. This column would include the payment since it was made during CY 2021.
- **Supplemental Rebate Percentage of Drug Spend for Contracted Products** - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

Summary of Supplemental Rebate Agreements during CY 2021	
Number of Contracts	189
Number of Unique Manufacturers Under Contract	183
Amount Plan Paid for Products During Contract Term	\$132,076,394
Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term	\$124,705,163
Total Supplemental Rebates Invoiced	\$ 5,427,189
Total Supplemental Rebates Collected	\$ 5,193,555
Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products	4.4%

Table 2 below lists the SRAs in place during CY 2021. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity Anthem Blue Cross and Blue Shield Healthcare Solutions has contracted with in the SRA.
- Effective Date - The start date of the SRA.
- Term Date - The end date of the SRA.

Table 2

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
60 DEGREES	1/1/2020	12/31/9999
ABBOTT DIABETES CARE	1/1/2020	12/31/2022
ABBVIE INC	1/1/2017	12/31/9999
ACERUS	4/1/2021	12/31/9999
ACORDA THERAPEUTICS INC	1/1/2020	12/31/2023
AERIE	1/1/2020	12/31/2022
AKARX INC	9/1/2020	12/31/9999
AKEBIA THERAPEUTICS INC	1/1/2020	12/31/9999
AKORN, INC	1/1/2020	12/31/2022
ALEXION PHARMACEUTICALS INC	1/1/2020	12/31/9999
ALFASIGMA USA	1/1/2020	12/31/9999
ALK ABELLO INC	1/1/2020	12/31/9999
ALKERMES INC	4/1/2020	12/31/2025
ALLERGAN PHARM	1/1/2020	12/31/9999
ALMATICA	10/1/2020	12/31/9999
ALMIRALL LLC	1/1/2020	12/31/9999
ALVOGEN INC	7/1/2021	12/31/9999
AMAG PHARMACEUTICALS, INC	1/1/2020	12/31/9999
AMARIN	1/1/2020	12/31/9999
AMGEN	1/1/2020	12/31/2022
AMNEAL PHARMACEUTICALS LLC	1/1/2020	12/31/9999
ANI PHARMACEUTICALS	7/1/2021	12/31/9999
ANTARES PHARMA INC	1/1/2020	12/31/9999
ARBOR	1/1/2020	12/31/2022
ARKRAY USA INC	1/1/2020	12/31/2023
ASCEND THERAPEUTICS US, LLC	1/1/2020	12/31/9999
ASCENDIS PHARMA ENDOCRINOLOGY	11/1/2021	12/31/9999
ASCENSIA DIABETES CARE US INC	1/1/2020	12/31/9999
ASEGUA	1/1/2020	12/31/9999
ASSERTIO	1/1/2020	12/31/9999

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
ASTELLAS PHARMA US	1/1/2020	12/31/9999
ASTRAZENECA	1/1/2020	12/31/9999
AVANIR PHARMACEUTICALS	1/1/2020	12/31/2023
AVION PHARMACEUTICALS	1/1/2020	12/31/9999
BANNER LIFE SCIENCES	10/1/2020	12/31/2023
BAUSCH HEALTH US LLC	7/1/2021	6/30/2022
BAUSCH HEALTH US LLC	1/1/2020	12/31/9999
BAYER	1/1/2020	12/31/2022
BIODELIVERY SCIENCES INT	7/1/2019	12/31/9999
BIOGEN	1/1/2020	12/31/9999
BIOHAVEN PHARMACEUTICALS	4/1/2020	12/31/9999
BIOVENTUS LLC	1/1/2020	12/31/9999
BOEHRINGER INGELHEIM	1/1/2020	12/31/9999
BOEHRINGER INGELHEIM	1/1/2020	12/31/9999
BRISTOL-MYERS SQUIBB	1/1/2020	12/31/9999
CELLTRION	10/1/2019	12/31/2022
CEQR CORPORATION	1/1/2021	12/31/9999
CHIESI USA	1/1/2020	12/31/9999
CLARUS THERAPEUTICS	7/1/2021	12/31/9999
CLOVIS ONCOLOGY INC	1/1/2020	12/31/2022
COHERUS BIOSCIENCES	1/1/2020	8/31/2023
COLLEGIUM PHARMACEUTICALS	7/1/2019	12/31/9999
COVIS PHARMA	1/1/2020	12/31/9999
CROWN LABORATORIES	1/1/2020	12/31/2022
CSL BEHRING LLC	1/1/2020	12/31/9999
CUMBERLAND PHARMACEUTICALS	1/1/2020	12/31/9999
CURRAX PHARMACEUTICALS LLC	1/1/2020	12/31/9999
CUTANEA LIFE SCIENCES INC	1/1/2020	12/31/9999
CYCLE PHARMACEUTICALS	1/1/2020	12/31/9999
DERMIRA, INC	1/1/2020	9/30/2022
DEXCOM	1/1/2020	12/31/9999
DIGESTIVE CARE	1/1/2020	12/31/9999
DUCHESNAY USA, INC	1/1/2020	8/31/2022
EGALET CORPORATION	1/1/2020	8/31/2023
EISAI INC	1/1/2020	12/31/9999
ELECTROCORE	1/1/2020	12/31/9999
ELI LILLY & COMPANY	1/1/2020	12/31/2023
EMBECTA CORP	1/1/2020	12/31/9999
EMD SERONO	1/1/2019	6/30/2022
EMERGENT DEVICES	1/1/2021	12/31/9999

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
ENCORE DERMATOLOGY, INC	1/1/2020	9/30/2021
ENDO PHARMACEUTICAL SOLUTIONS	10/1/2019	12/31/2023
EPI HEALTH LLC	1/1/2020	12/31/9999
ESPERION THERAPEUTICS	4/1/2020	12/31/2022
EXELIXIS INC	1/1/2020	12/31/9999
EXELTIS USA DERMATOLOGY	1/1/2020	12/31/9999
EYEVANCE	1/1/2020	12/31/2022
FERRING	1/1/2020	12/31/9999
FIDIA PHARMA USA INC	1/1/2020	12/31/9999
FORTOVIA THERAPEUTICS	1/1/2020	5/31/2022
FORWARD SCIENCE	1/1/2020	12/31/9999
FOUGERA PHARMACEUTICALS INC	1/1/2020	12/31/2021
FRESENIUS USA	1/1/2020	12/31/2022
GALDERMA	1/1/2021	12/31/2023
GALEN	1/1/2020	2/28/2022
GENENTECH	1/1/2020	12/31/2022
GENESIS HEALTH TECHNOLOGIES	1/1/2020	12/31/9999
GILEAD SCIENCES INC	1/1/2020	12/31/9999
GLAXOSMITHKLINE	1/1/2019	12/31/2021
GLAXOSMITHKLINE	1/1/2021	12/31/9999
GLENMARK THERAPEUTICS INC	1/1/2020	12/31/9999
GREENWICH BIOSCIENCES	1/1/2020	12/31/2022
GREER LABORATORIES, INC	1/1/2020	12/31/9999
GRIFOLS USA, LLC	1/1/2020	12/31/9999
HELSINN THERAPEUTICS	1/1/2020	8/31/2021
HIKMA AMERICAS	1/1/2020	12/31/9999
HORIZON MEDICINES LLC	1/1/2020	12/31/9999
HTL-STREFA	4/1/2021	12/31/9999
IMPEL PHARMACEUTICALS	10/1/2021	12/31/9999
INDIVIOR	7/1/2019	12/31/9999
INSMED	7/1/2019	12/31/9999
INSULET	1/1/2020	12/31/9999
INTUITY MEDICAL	10/1/2021	12/31/9999
IPSEN BIOPHARMACEUTICALS INC	1/1/2020	12/31/9999
IRONSHORE	1/1/2020	12/31/9999
JAZZ	4/1/2020	12/31/2022
JOHNSON and JOHNSON	1/1/2017	12/31/2022
JOURNEY MEDICAL	9/1/2020	12/31/9999
KALA PHARMACEUTICALS INC	1/1/2020	12/31/2022
KOWA PHARMACEUTICALS	1/1/2020	12/31/9999

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
KYOWA KIRIN	1/1/2020	12/31/9999
LEO PHARMA, INC	1/1/2020	12/31/9999
LIFESCAN	1/1/2020	12/31/9999
LUPIN PHARMACEUTICALS, INC	7/1/2021	12/31/9999
LUPIN PHARMACEUTICALS, INC	7/1/2013	6/30/2021
MALLINCKRODT	10/1/2019	12/31/9999
MANNKIND CORPORATION	1/1/2020	12/31/9999
MAYNE PHARMA	1/1/2020	12/31/9999
MEDEXUS PHARMA	1/1/2020	12/31/9999
MELINTA THERAPEUTICS LLC	1/1/2020	12/31/9999
MERCK & CO, INC	1/1/2020	12/31/9999
METUCHEN	1/1/2020	12/31/9999
MILLENNIUM PHARMACEUTICALS	1/1/2021	12/31/2023
MILLICENT	1/1/2020	12/31/9999
MINIMED DISTRIBUTION CORP	1/1/2020	12/31/9999
MISSION	1/1/2020	12/31/9999
MYLAN PHARMACEUTICALS INC	1/1/2020	12/31/2022
NABRIVA	1/1/2020	12/31/9999
NEOS THERAPEUTICS LP	1/1/2020	12/31/2022
NESTLE HEALTH SCIENCE	1/1/2021	12/31/9999
NEURELIS	10/1/2020	12/31/9999
NEUROCRINE BIOSCIENCES INC	1/1/2020	12/31/9999
NODEN PHARMA USA	1/1/2020	12/31/9999
NOVARTIS	1/1/2020	12/31/9999
NOVEN THERAPEUTICS LLC	1/1/2020	12/31/9999
NOVO NORDISK	1/1/2020	12/31/9999
NOVO NORDISK	3/1/2020	12/31/9999
OCTAPHARMA USA	7/1/2021	12/31/9999
OPKO PHARMACEUTICALS LLC	1/1/2020	12/31/9999
OPTINOSE US, INC	1/1/2020	12/31/9999
OREXO	7/1/2019	12/31/9999
ORTHOGENRX	1/1/2020	7/31/2023
OTSUKA	1/1/2020	12/31/9999
PADAGIS US LLC	1/1/2020	12/31/9999
PARATEK PHARMACEUTICALS, INC	1/1/2020	12/31/2022
PARI RESPIRATORY	1/1/2020	12/31/9999
PFIZER US PHARM	1/1/2020	12/31/9999
PHARMING HEALTHCARE INC	1/1/2020	12/31/9999
PIERRE FABRE PHARMA INC	1/1/2020	12/31/9999
PURDUE PHARMA	10/1/2019	12/31/9999

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
RADIUS HEALTH INC	1/1/2020	12/31/9999
RB HEALTH (US) LLC	1/1/2020	12/31/9999
REDHILL BIOPHARMA	1/1/2020	12/31/2023
REGENERON PHARMACEUTICALS INC	10/1/2020	12/31/9999
RESILIA PHARMACEUTICALS	10/1/2021	12/31/9999
ROCHE DIAGNOSTICS	1/1/2020	12/31/2022
SANDOZ INC	4/1/2020	12/31/9999
SANOFI - AVENTIS	7/1/2013	12/31/9999
SCILEX PHARMACEUTICALS INC	7/1/2019	12/31/9999
SEBELA PHARMACEUTICALS INC	1/1/2021	12/31/9999
SECURA BIO	1/1/2021	12/31/9999
SHIONOGI & COMPANY, INC	1/1/2020	12/31/9999
SK LIFE SCIENCE	4/1/2020	12/31/9999
SOBI INC	1/1/2020	12/31/2024
SUN PHARMA INDUSTRIES INC	1/1/2019	12/31/2023
SUN PHARMA INDUSTRIES INC	1/1/2020	12/31/9999
SUNOVION	1/1/2020	12/31/2022
SUPERNUS PHARMACEUTICALS, INC	1/1/2020	12/31/9999
TAKEDA	10/1/2019	12/31/9999
TERSERA THERAPEUTICS	1/1/2020	12/31/9999
TEVA	1/1/2020	12/31/9999
THERAPEUTICSMD INC	1/1/2020	12/31/9999
TOLMAR PHARMACEUTICALS INC	10/1/2020	12/31/9999
TRAVERE THERAPEUTICS INC	1/1/2020	12/31/9999
TRIS PHARMA	1/1/2020	12/31/9999
TRIVIDIA HEALTH	1/1/2020	12/31/9999
UCB INC	1/1/2020	9/30/2022
UPSHER-SMITH	1/1/2020	12/31/9999
UROVANT	8/1/2021	12/31/9999
VELOXIS PHARMACEUTICALS	1/1/2020	12/31/9999
VERTICAL PHARMACEUTICALS	1/1/2020	12/31/9999
VIFOR PHARMA, INC	1/1/2020	12/31/2022
VIVUS	1/1/2020	12/31/9999
VYERA PHARMACEUTICALS	1/1/2020	12/31/9999
VYNE PHARMACEUTICALS INC	1/1/2021	2/28/2023
WOMENS CHOICE PHARMACEUTICALS	1/1/2020	12/31/9999
XERIS	3/1/2020	12/31/9999
ZEALAND PHARMA US INC	1/1/2020	12/31/9999
ZIMMER US, INC	1/1/2020	12/31/2022

Table 3 below provides the value for each individual SRA. Table 3 is sorted by descending contract value.

Table 3 Column Definitions:

- Manufacturer Name - The name of the entity Anthem Blue Cross and Blue Shield Healthcare Solutions has contracted within the SRA.
- Amount Plan Paid for Products During Contract Term - The amount paid for all drugs subject to a manufacturer’s SRA during CY 2021.
 - Example: Drug “A” was subject to an SRA from 06/01/2019 to 03/31/2021. This column would include the amount paid for Drug “A” for claims paid from 01/01/2021 to 03/31/2021.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2021 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.

Table 3

Supplemental Rebate Agreements during CY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
Manufacturer 1	\$8,238,823.87	\$7,853,775.18	\$1,601,231.66	\$1,591,290.90
Manufacturer 2	\$14,155,066.90	\$14,108,320.50	\$831,812.67	\$796,780.89
Manufacturer 3	\$775,809.11	\$710,139.15	\$600,496.27	\$385,066.34
Manufacturer 4	\$3,788,746.69	\$3,757,337.94	\$495,111.67	\$474,317.31
Manufacturer 5	\$681,484.09	\$642,333.44	\$457,747.00	\$457,747.00
Manufacturer 6	\$6,491,634.78	\$6,108,598.28	\$454,645.84	\$410,273.02
Manufacturer 7	\$1,377,150.15	\$1,377,150.15	\$280,330.29	\$280,330.29
Manufacturer 8	\$380,931.68	\$380,675.89	\$134,338.89	\$134,338.94
Manufacturer 9	\$2,790,293.10	\$2,698,693.25	\$119,278.61	\$117,627.09
Manufacturer 10	\$3,245,352.42	\$3,245,076.46	\$83,695.26	\$83,695.21
Manufacturer 11	\$811,785.33	\$773,693.60	\$57,159.06	\$57,159.15
Manufacturer 12	\$3,862,692.73	\$3,645,941.18	\$47,414.53	\$47,370.28
Manufacturer 13	\$486,410.67	\$451,466.89	\$37,548.60	\$94,215.49
Manufacturer 14	\$888,137.90	\$879,275.98	\$35,683.26	\$35,683.26
Manufacturer 15	\$351,584.06	\$329,447.25	\$32,381.52	\$61,973.64
Manufacturer 16	\$3,665,924.05	\$3,610,596.78	\$29,486.40	\$29,486.37
Manufacturer 17	\$8,850,376.61	\$8,606,268.15	\$24,737.39	\$24,738.05
Manufacturer 18	\$132,805.70	\$126,567.08	\$23,341.34	\$22,194.30
Manufacturer 19	\$582,467.62	\$382,713.79	\$18,678.09	\$18,392.20
Manufacturer 20	\$194,341.51	\$180,300.73	\$17,079.45	\$17,045.95
Manufacturer 21	\$43,940.22	\$43,940.22	\$13,228.31	\$11,892.78
Manufacturer 22	\$5,711,037.03	\$5,361,213.33	\$9,226.96	\$24,066.78
Manufacturer 23	\$1,121,045.96	\$1,101,484.13	\$7,782.78	\$7,782.74
Manufacturer 24	\$64,256.69	\$61,792.01	\$7,062.71	\$6,547.76
Manufacturer 25	\$26,761.71	\$24,418.03	\$4,196.90	\$45.54
Manufacturer 26	\$36,806.47	\$36,806.47	\$2,231.96	\$2,231.95
Manufacturer 27	\$444,904.98	\$444,904.98	\$1,428.45	\$1,428.43

Manufacturer 28	\$737.05	\$616.62	\$309.03	\$309.02
Manufacturer 29	\$39,060.05	\$37,490.94	\$69.85	\$69.86
Manufacturer 30	\$615.34	\$540.62	\$21.96	\$21.96
Manufacturer 31	\$45,415.90	\$42,083.04	\$15.44	\$15.45
Manufacturer 32	\$4,197,555.96	\$4,075,453.41	(582.63)	(582.61)
Manufacturer 33	\$18,492,687.75	\$17,741,364.44	-	-
Manufacturer 34	\$5,308,402.39	\$5,065,749.85	-	-
Manufacturer 35	\$3,229,862.26	\$3,056,808.72	-	-
Manufacturer 36	\$3,134,139.85	\$2,947,486.10	-	-
Manufacturer 37	\$2,918,361.57	\$2,313,412.71	-	-
Manufacturer 38	\$2,103,883.12	\$2,056,763.27	-	-
Manufacturer 39	\$1,918,458.82	\$1,868,169.03	-	-
Manufacturer 40	\$1,746,369.25	\$1,663,637.94	-	-
Manufacturer 41	\$1,723,778.54	\$1,731,272.84	-	-
Manufacturer 42	\$1,594,034.23	\$1,286,974.80	-	-
Manufacturer 43	\$1,590,415.37	\$1,067,781.58	-	-
Manufacturer 44	\$1,457,696.13	\$1,391,793.73	-	-
Manufacturer 45	\$1,168,362.90	\$1,024,466.55	-	-
Manufacturer 46	\$907,225.81	\$724,087.41	-	-
Manufacturer 47	\$853,220.32	\$432,864.14	-	-
Manufacturer 48	\$825,867.47	\$795,948.36	-	-
Manufacturer 49	\$782,500.21	\$500,602.57	-	-
Manufacturer 50	\$723,168.28	\$685,933.96	-	-
Manufacturer 51	\$708,347.38	\$681,353.47	-	-
Manufacturer 52	\$687,191.89	\$686,574.73	-	-
Manufacturer 53	\$580,752.18	\$557,591.39	-	-
Manufacturer 54	\$510,477.96	\$285,041.21	-	-
Manufacturer 55	\$370,828.92	\$365,504.24	-	-
Manufacturer 56	\$287,691.04	\$191,647.00	-	-
Manufacturer 57	\$270,512.80	\$255,186.04	-	-
Manufacturer 58	\$261,094.56	\$279,441.92	-	-
Manufacturer 59	\$253,337.80	\$129,465.20	-	-
Manufacturer 60	\$239,692.15	\$226,753.00	-	-
Manufacturer 61	\$229,910.00	\$219,610.38	-	-
Manufacturer 62	\$227,749.81	\$227,152.41	-	-
Manufacturer 63	\$213,280.95	\$200,504.70	-	-
Manufacturer 64	\$203,850.97	\$214,080.26	-	-
Manufacturer 65	\$203,312.15	\$117,257.67	-	-
Manufacturer 66	\$201,265.19	\$194,064.34	-	-
Manufacturer 67	\$191,705.33	\$182,128.36	-	-
Manufacturer 68	\$179,636.19	\$169,951.67	-	-
Manufacturer 69	\$179,176.34	\$169,889.73	-	-
Manufacturer 70	\$167,916.44	\$167,916.44	-	-
Manufacturer 71	\$159,401.48	\$159,401.48	-	-
Manufacturer 72	\$147,733.33	\$77,679.53	-	-
Manufacturer 73	\$119,194.28	\$45,297.28	-	-
Manufacturer 74	\$107,468.11	\$105,554.53	-	-
Manufacturer 75	\$107,341.03	\$103,173.57	-	-
Manufacturer 76	\$105,311.19	\$97,663.76	-	-
Manufacturer 77	\$96,565.72	\$91,533.03	-	-
Manufacturer 78	\$88,533.71	\$85,822.35	-	-
Manufacturer 79	\$79,213.50	\$79,213.50	-	-
Manufacturer 80	\$74,778.14	\$70,849.34	-	-
Manufacturer 81	\$61,173.96	\$57,886.70	-	-
Manufacturer 82	\$54,946.81	\$51,449.76	-	-
Manufacturer 83	\$53,607.82	\$51,285.90	-	-
Manufacturer 84	\$49,801.63	\$46,896.57	-	-
Manufacturer 85	\$44,253.70	\$41,886.28	-	-
Manufacturer 86	\$42,595.25	\$40,211.33	-	-

Manufacturer 87	\$39,087.02	\$34,010.92	-	-
Manufacturer 88	\$35,669.00	\$35,529.23	-	-
Manufacturer 89	\$34,735.52	\$33,206.62	-	-
Manufacturer 90	\$33,522.77	\$32,062.70	-	-
Manufacturer 91	\$31,404.13	\$27,654.27	-	-
Manufacturer 92	\$29,962.34	\$29,759.61	-	-
Manufacturer 93	\$29,942.36	\$28,326.45	-	-
Manufacturer 94	\$19,480.63	\$18,522.64	-	-
Manufacturer 95	\$18,013.03	\$16,881.42	-	-
Manufacturer 96	\$17,165.79	\$16,581.90	-	-
Manufacturer 97	\$17,099.60	\$16,192.66	-	-
Manufacturer 98	\$16,306.93	\$15,192.86	-	-
Manufacturer 99	\$16,009.50	\$15,254.16	-	-
Manufacturer 100	\$15,440.62	\$15,137.05	-	-
Manufacturer 101	\$15,317.73	\$14,053.08	-	-
Manufacturer 102	\$15,075.55	\$14,467.83	-	-
Manufacturer 103	\$11,949.35	\$11,898.54	-	-
Manufacturer 104	\$11,825.48	\$11,462.93	-	-
Manufacturer 105	\$11,360.56	\$10,935.51	-	-
Manufacturer 106	\$10,543.43	\$9,810.94	-	-
Manufacturer 107	\$9,866.31	\$9,183.42	-	-
Manufacturer 108	\$9,664.40	\$8,900.51	-	-
Manufacturer 109	\$7,956.00	\$7,956.00	-	-
Manufacturer 110	\$7,665.70	\$7,060.87	-	-
Manufacturer 111	\$6,850.13	\$6,850.13	-	-
Manufacturer 112	\$6,651.47	\$5,961.83	-	-
Manufacturer 113	\$6,423.06	\$5,885.55	-	-
Manufacturer 114	\$5,897.97	\$5,897.97	-	-
Manufacturer 115	\$5,876.97	\$5,485.00	-	-
Manufacturer 116	\$5,636.15	\$5,423.45	-	-
Manufacturer 117	\$5,369.42	\$4,882.06	-	-
Manufacturer 118	\$5,296.68	\$4,925.21	-	-
Manufacturer 119	\$5,133.77	\$4,840.60	-	-
Manufacturer 120	\$4,467.13	\$4,294.87	-	-
Manufacturer 121	\$4,283.20	\$4,135.72	-	-
Manufacturer 122	\$3,689.62	\$3,067.38	-	-
Manufacturer 123	\$3,566.08	\$3,442.44	-	-
Manufacturer 124	\$3,258.72	\$2,987.84	-	-
Manufacturer 125	\$3,222.61	\$3,537.11	-	-
Manufacturer 126	\$2,617.47	\$2,423.88	-	-
Manufacturer 127	\$2,486.20	\$2,403.35	-	-
Manufacturer 128	\$1,425.63	\$1,311.56	-	-
Manufacturer 129	\$1,389.57	\$1,261.34	-	-
Manufacturer 130	\$1,373.61	\$1,305.72	-	-
Manufacturer 131	\$1,041.78	\$953.04	-	-
Manufacturer 132	\$989.82	\$989.82	-	-
Manufacturer 133	\$762.56	\$661.40	-	-
Manufacturer 134	\$754.71	\$116.40	-	-
Manufacturer 135	\$569.76	\$704.35	-	-
Manufacturer 136	\$256.30	\$219.87	-	-
Manufacturer 137	-	-	-	-
Manufacturer 138	-	-	-	-
Manufacturer 139	-	-	-	-
Manufacturer 140	-	-	-	-
Manufacturer 141	-	-	-	-
Manufacturer 142	-	-	-	-
Manufacturer 143	-	-	-	-
Manufacturer 144	-	-	-	-
Manufacturer 145	-	-	-	-

Manufacturer 146	-	-	-	-
Manufacturer 147	-	-	-	-
Manufacturer 148	-	-	-	-
Manufacturer 149	-	-	-	-
Manufacturer 150	-	-	-	-
Manufacturer 151	-	-	-	-
Manufacturer 152	-	-	-	-
Manufacturer 153	-	-	-	-
Manufacturer 154	-	-	-	-
Manufacturer 155	-	-	-	-
Manufacturer 156	-	-	-	-
Manufacturer 157	-	-	-	-
Manufacturer 158	-	-	-	-
Manufacturer 159	-	-	-	-
Manufacturer 160	-	-	-	-
Manufacturer 161	-	-	-	-
Manufacturer 162	-	-	-	-
Manufacturer 163	-	-	-	-
Manufacturer 164	-	-	-	-
Manufacturer 165	-	-	-	-
Manufacturer 166	-	-	-	-
Manufacturer 167	-	-	-	-
Manufacturer 168	-	-	-	-
Manufacturer 169	-	-	-	-
Manufacturer 170	-	-	-	-
Manufacturer 171	-	-	-	-
Manufacturer 172	-	-	-	-
Manufacturer 173	-	-	-	-
Manufacturer 174	-	-	-	-
Manufacturer 175	-	-	-	-
Manufacturer 176	-	-	-	-
Manufacturer 177	-	-	-	-
Manufacturer 178	-	-	-	-
Manufacturer 179	-	-	-	-
Manufacturer 180	-	-	-	-
Manufacturer 181	-	-	-	-
Manufacturer 182	-	-	-	-
Manufacturer 183	-	-	-	-

The next two tables provide additional information as required by Senate Bill 378 (2019). Table 4 below provides the values and total amounts of dispensing fees paid by Anthem Blue Cross and Blue Shield Healthcare Solutions to pharmacies.

Table 4 Column Definitions:

- Retail 30 Days – Dispensing fee cost for 0–30-day supplies at a retail location
- Retail >30 Days – Dispensing fee cost for >30-day supplies at a retail location
- Mail Order – Dispensing fee cost for mail order pharmacies
- Specialty – Dispensing fees cost for specialty pharmacies

Table 4

Dispensing Fees during CY 2021				
Type of Dispensing Fee:	Retail 30 Days	Retail >30 Days	Mail Order	Specialty
Dispensing Fee	\$0.57	\$0.71	\$0.00	\$0.58
Totals	\$1,842,772	\$10,582	\$0.00	\$51,649
Grand Total	\$1,905,003			

Table 5 below provides a summary of measures employed by the pharmacy benefit manager contracted by Anthem Blue Cross and Blue Shield Healthcare Solutions to control outpatient prescription drug costs.

Table 5 Row Definitions:

- Utilization Management – Measures to control use of pharmacy services for medical necessity and appropriateness to provide efficacious and cost-effective medications. Examples of utilization management include but not limited to prior authorization, step therapy, and quantity limits.
- Prior Authorization – Is a prospective review for an approval for the use of a medication.
- Step Therapy – Is a utilization management program that requires a patient to try a lower cost medication before stepping up to a similar-acting more expensive medication.
- Quantity limits – Limits medication use to the maximum dose of a medication.
- Pharmacy Networks – Is a group of pharmacies contracted with the payer where patients can fill medications.
- Preferred Drug List – Is a list of preferred medications that requires a patient to try the preferred medication before using a non-preferred medication.
- Prospective Drug Utilization Review (ProDUR) Activities – ProDUR activities are automated, structured, ongoing review of prescribing, dispensing and use of medications.

Table 5

Measures to Control Costs during CY 2021		
Utilization Management	Prior Authorization	Yes
	Step Therapy	Yes
	Quantity Limits	Yes
Pharmacy Networks		Yes
Preferred Drug List		Yes
ProDUR Activities		Yes

Health Plan of Nevada

A UnitedHealthcare Company 

Supplemental Rebate Agreement Report Calendar Year 2021

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid Drug Rebate Program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal Unit Rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter into separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies and contracted Managed Care Organizations (MCOs) to ensure preferred status on the respective Preferred Drug Lists (PDL).

Generally, SRAs are in effect for one calendar year beginning on January 1st and terminating on December 31st. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31st end date such as a product moving to non-preferred status or to coincide with planned Pharmacy & Therapeutics Committee reviews and recommendations.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- "Percentage of WAC" - set percentage of the drug's published wholesale acquisition cost (WAC).
- "GNUP" (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
 - In the event a drug's WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
 - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer's SRA with Health Plan of Nevada Medicaid through its Pharmacy Benefit Manager (PBM).

Health Plan of Nevada Medicaid had had 98 SRAs in place that were in effect during Calendar Year 2021 (January 1, 2021 – December 31, 2021) (hereinafter referred to as CY 2021). Table 1 below summarizes the agreements.

Table 1 Row Definitions:

- **Number of Contracts** - The count of signed SRAs that were in force during some period within CY 2021.
- **Number of Unique Manufacturers Under Contract** - The count of unique manufacturers with a signed SRA in force during some period within CY 2021.
- **Amount Plan Paid for Products During Contract Term** - The amount Health Plan of Nevada paid for all drug utilization subject to a manufacturer’s SRA during CY 2021.
 - **Example:** Drug “A” was subject to an SRA from 04/01/2021 to 12/31/2021 would include the amount paid for Drug “A” for claims paid from 04/01/2021 to 12/31/2021.
- **Amount Plan Paid to Pharmacies/Providers for Products Under Contract** – The amount Health Plan of Nevada paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2021.
- **Total Supplemental Rebates Invoiced** - The supplemental rebate amount invoiced during CY 2021 to manufacturers for drugs subject to SRAs.
- **Total Supplemental Rebates Collected** - The supplemental rebate amount collected during CY 2021 From manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.
 - **Example:** Manufacturer B was invoiced \$100.00 for supplemental rebates in November 2020 and remitted payment in January 2021. This column would include the payment since it was made during CY 2021.
- **Supplemental Rebate Percentage of Drug Spend for Contracted Products** - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

Summary of Supplemental Rebate Agreements during CY 2021	
Number of Contracts	98
Number of Unique Manufacturers Under Contract	41
Amount Plan Paid for Products During Contract Term	\$70,984,615.45
Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term	\$70,984,615.45
Total Supplemental Rebates Invoiced	\$11,941,312.18
Total Supplemental Rebates Collected	\$11,747,129.89
Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products	16.82%

Table 2 below lists the SRAs in place during CY 2021. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity Health Plan of Nevada and its PBM have contracted with in the SRA.
- Effective Date - The start date of the SRA.
- Term Date - The end date of the SRA.

Table 2

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
Abbott Diabetes Care Sales Corporation	1/1/2021	12/31/2021
AbbVie US LLC	1/1/2021	12/31/2021
Alkermes, Inc.	1/1/2021	12/31/2021
Amgen USA Inc.	1/1/2021	12/31/2021
Asegua Therapeutics LLC	1/1/2021	12/31/2021
Astra Zeneca	1/1/2021	12/31/2021
Bausch & Lomb Americas Inc.	10/1/2021	12/31/2021
Becton, Dickinson and Company	1/1/2021	12/31/2021
Biogen Idec US Corporation	7/1/2021	12/31/2021
Biohaven Pharmaceuticals, Inc.	1/1/2021	12/31/2021
Boehringer Ingelheim Pharmaceuticals Inc	1/1/2021	12/31/2021
Dexcom Inc	1/1/2021	12/31/2021
Eli Lilly and Company	1/1/2021	12/31/2021
Ferring Pharmaceuticals Inc	1/1/2021	12/31/2021
Fresenius Kabi, LLC	1/1/2021	12/31/2021
GlaxoSmithKline	1/1/2021	12/31/2021
Hikma Specialty USA Inc.	1/1/2021	12/31/2021
Johnson & Johnson Health Care Systems Inc	1/1/2021	12/31/2021
Lifescan, Inc.	1/1/2021	3/31/2021
Merck Sharp & Dohme Corp	1/1/2021	12/31/2021
Neurocrine Biosciences, Inc.	1/1/2021	12/31/2021
Novartis Pharmaceuticals Corporation	1/1/2021	12/31/2021
Organon LLC	7/1/2021	12/31/2021
Otsuka America Pharmaceutical Inc	1/1/2021	12/31/2021
Paratek Pharmaceuticals Inc	1/1/2021	12/31/2021
Pfizer Inc	1/1/2021	12/31/2021

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
Radius Health Inc	1/1/2021	12/31/2021
Redhill Biopharma	1/1/2021	12/31/2021
Regeneron Healthcare Solutions Inc.	1/1/2021	12/31/2021
Relypsa Inc	1/1/2021	12/31/2021
Sandoz, Inc.	1/1/2021	12/31/2021
sanofi aventis Puerto Rico Inc.	1/1/2021	12/31/2021
Sanofi Aventis US	1/1/2021	12/31/2021
Shionogi (fka Sciele - First Horizon)	1/1/2021	12/31/2021
Takeda Pharmaceuticals America, Inc.	7/1/2021	12/31/2021
TerSera Therapeutics LLC	1/1/2021	12/31/2021
Teva Neuroscience, Inc.	1/1/2021	12/31/2021
UCB Inc	1/1/2021	12/31/2021
Viiv Healthcare	1/1/2021	12/31/2021
ViiV Healthcare Puerto Rico LLC	1/1/2021	12/31/2021
Xeris Pharmaceuticals, Inc.	1/1/2021	12/31/2021

Table 3 below provides the value for each individual SRA. Table 3 is sorted by descending contract value.

Table 3 Column Definitions:

- Manufacturer Name - The blinded name of the entity Health Plan of Nevada and its PBM have contracted within the SRA.
- Amount Plan Paid for Products During Contract Term - The amount paid for all drugs subject to a manufacturer's SRA during CY 2021.
 - Example: Drug "A" was subject to an SRA from 06/01/2019 to 03/31/2021. This column would include the amount paid for Drug "A" for claims paid from 01/01/2021 to 03/31/2021.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount paid to pharmacies and providers for drugs subject to a manufacturer's SRA during CY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2021 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.

Table 3

Supplemental Rebate Agreements during CY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
NVMCO HPN SRA 3	\$ 16,109,939.62	\$ 16,109,939.62	\$ 4,213,647.49	\$ 4,118,672.35
NVMCO HPN SRA 23	\$ 3,127,047.07	\$ 3,127,047.07	\$ 2,707,857.12	\$ 2,735,394.19
NVMCO HPN SRA 39	\$ 18,138,863.51	\$ 18,138,863.51	\$ 1,011,176.31	\$ 991,458.05
NVMCO HPN SRA 10	\$ 2,296,689.24	\$ 2,296,689.24	\$ 1,006,124.99	\$ 1,003,700.18
NVMCO HPN SRA 8	\$ 2,393,063.36	\$ 2,393,063.36	\$ 611,324.20	\$ 574,409.24
NVMCO HPN SRA 35	\$ 4,339,991.37	\$ 4,339,991.37	\$ 516,319.09	\$ 512,208.38
NVMCO HPN SRA 27	\$ 3,890,724.21	\$ 3,890,724.21	\$ 307,295.99	\$ 315,362.98
NVMCO HPN SRA 15	\$ 2,772,450.69	\$ 2,772,450.69	\$ 224,819.87	\$ 216,208.09
NVMCO HPN SRA 16	\$ 5,799,360.42	\$ 5,799,360.42	\$ 206,063.41	\$ 181,651.68
NVMCO HPN SRA 22	\$ 431,214.75	\$ 431,214.75	\$ 187,282.62	\$ 180,942.28
NVMCO HPN SRA 12	\$ 1,186,656.00	\$ 1,186,656.00	\$ 112,480.00	\$ 112,487.46
NVMCO HPN SRA 36	\$ 768,142.82	\$ 768,142.82	\$ 89,484.49	\$ 89,763.83
NVMCO HPN SRA 40	\$ 763,755.52	\$ 763,755.52	\$ 77,916.86	\$ 76,053.69
NVMCO HPN SRA 33	\$ 215,531.65	\$ 215,531.65	\$ 75,441.43	\$ 74,595.88
NVMCO HPN SRA 19	\$ 1,223,429.46	\$ 1,223,429.46	\$ 73,052.16	\$ 73,113.55
NVMCO HPN SRA 2	\$ 1,393,701.65	\$ 1,393,701.65	\$ 72,903.45	\$ 71,725.47
NVMCO HPN SRA 30	\$ 326,816.90	\$ 326,816.90	\$ 57,632.99	\$ 40,418.98
NVMCO HPN SRA 14	\$ 2,278,527.74	\$ 2,278,527.74	\$ 52,877.00	\$ 48,482.23
NVMCO HPN SRA 5	\$ 520,310.23	\$ 520,310.23	\$ 46,578.23	\$ 46,181.29
NVMCO HPN SRA 21	\$ 111,816.03	\$ 111,816.03	\$ 46,492.97	\$ 42,948.75
NVMCO HPN SRA 41	\$ 1,115,004.35	\$ 1,115,004.35	\$ 45,001.40	\$ 44,271.95
NVMCO HPN SRA 7	\$ 104,348.33	\$ 104,348.33	\$ 37,117.51	\$ 35,808.12
NVMCO HPN SRA 17	\$ 140,594.35	\$ 140,594.35	\$ 31,118.16	\$ 31,868.14
NVMCO HPN SRA 6	\$ 301,596.82	\$ 301,596.82	\$ 23,811.40	\$ 22,923.15
NVMCO HPN SRA 31	\$ 254,211.65	\$ 254,211.65	\$ 20,175.40	\$ 19,890.11
NVMCO HPN SRA 18	\$ 81,755.12	\$ 81,755.12	\$ 19,020.14	\$ 19,261.50
NVMCO HPN SRA 11	\$ 43,140.43	\$ 43,140.43	\$ 10,752.70	\$ 10,722.03
NVMCO HPN SRA 38	\$ 57,103.84	\$ 57,103.84	\$ 10,662.45	\$ 10,592.91
NVMCO HPN SRA 29	\$ 140,830.20	\$ 140,830.20	\$ 9,441.22	\$ 8,311.94
NVMCO HPN SRA 20	\$ 322,308.62	\$ 322,308.62	\$ 8,418.61	\$ 8,376.40
NVMCO HPN SRA 9	\$ 92,796.56	\$ 92,796.56	\$ 7,386.38	\$ 7,378.81

Supplemental Rebate Agreements during CY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
NVMCO HPN SRA 32	\$ 49,144.93	\$ 49,144.93	\$ 5,793.66	\$ 5,866.20
NVMCO HPN SRA 13	\$ 54,661.69	\$ 54,661.69	\$ 5,427.59	\$ 5,415.96
NVMCO HPN SRA 37	\$ 62,405.01	\$ 62,405.01	\$ 3,713.94	\$ 3,947.90
NVMCO HPN SRA 24	\$ 12,862.68	\$ 12,862.68	\$ 1,849.92	\$ 1,866.35
NVMCO HPN SRA 26	\$ 25,943.94	\$ 25,943.94	\$ 1,814.16	\$ 1,806.29
NVMCO HPN SRA 25	\$ 15,549.15	\$ 15,549.15	\$ 1,785.49	\$ 1,777.75
NVMCO HPN SRA 28	\$ 5,180.24	\$ 5,180.24	\$ 562.10	\$ 578.71
NVMCO HPN SRA 4	\$ 6,141.04	\$ 6,141.04	\$ 307.78	\$ 307.79
NVMCO HPN SRA 1	\$ 1,070.74	\$ 1,070.74	\$ 282.86	\$ 280.69
NVMCO HPN SRA 34	\$ 9,933.52	\$ 9,933.52	\$ 98.64	\$ 98.64

The next two tables provide additional information as required by Senate Bill 378 (2019). Table 4 below provides the values and total amounts of dispensing fees paid by Health Plan of Nevada and its PBM to pharmacies.

Table 4 Column Definitions:

- Retail 30 Days – Dispensing fee cost for 0–30-day supplies at a retail location
- Retail >30 Days – Dispensing fee cost for >30-day supplies at a retail location
- Mail Order – Dispensing fee cost for mail order pharmacies
- Specialty – Dispensing fees cost for specialty pharmacies

Table 4

Dispensing Fees during CY 2021				
Type of Dispensing Fee:	Retail 30 Days	Retail >30 Days	Mail Order	Specialty
Dispensing Fee	\$1.26	\$0.04	\$1.26	\$0.04
Totals	\$3,169,960.48	\$3,213.67	\$16,345.25	\$409.75
Grand Total	\$3,189,929.15			

Table 5 below provides a summary of measures employed by Health Plan of Nevada and its PBM to control outpatient prescription drug costs.

Table 5 Row Definitions:

- Utilization Management – Measures to control use of pharmacy services for medical necessity and appropriateness to provide efficacious and cost-effective medications. Examples of utilization management include but not limited to prior authorization, step therapy, and quantity limits.
- Prior Authorization – Is a prospective review for an approval for the use of a medication.
- Step Therapy – Is a utilization management program that requires a patient to try a lower cost medication before stepping up to a similar-acting more expensive medication.
- Quantity limits – Limits medication use to the maximum dose of a medication.
- Pharmacy Networks – Is a group of pharmacies contracted with the payer where patients can fill medications.
- Preferred Drug List – Is a list of preferred medications that requires a patient to try the preferred medication before using a non-preferred medication.
- Prospective Drug Utilization Review (ProDUR) Activities – ProDUR activities are automated, structured, ongoing review of prescribing, dispensing and use of medications.

Table 5

Measures to Control Costs during CY 2021		
Utilization Management	Prior Authorization	Yes
	Step Therapy	Yes
	Quantity Limits	Yes
Pharmacy Networks		Yes
Preferred Drug List		Yes
ProDUR Activities		Yes

SilverSummit Healthplan Supplemental Rebate Agreement Report Calendar Year 2021

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid Drug Rebate Program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal Unit Rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter into separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists (PDL).

The SRAs are between the manufacturers and the Pharmacy Benefit Manager (PBM), CVS/Caremark, on behalf of SilverSummit Healthplan. Generally, the SRAs are in effect for one calendar year beginning on January 1st and terminating on December 31st. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31st end date such as a product moving to non-preferred status or to coincide with a planned SilverSummit Healthplan Pharmacy & Therapeutics (P&T) Committee.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- "Percentage of WAC" - set percentage of the drug's published wholesale acquisition cost (WAC).
- "GNUP" (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
 - In the event a drug's WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
 - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place for price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer's SRA with the PBM (CVS/Caremark) on behalf of SilverSummit Healthplan.

SRAs provides confidentiality assurance that the Healthplan’s PBM (CVS/Caremark) and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing related terms and conditions.

SilverSummit Healthplan’s PBM had 189 SRAs in place that were in effect during Calendar Year 2021 (January 1, 2021 – December 31, 2021) (hereinafter referred to as CY 2021). Table 1 below summarizes the agreements.

Table 1 Row Definitions:

- **Number of Contracts** - The count of signed SRAs that were in force during some period within CY 2021.
- **Number of Unique Manufacturers Under Contract** - The count of unique manufacturers with a signed SRA in force during some period within CY 2021.
- **Amount Plan Paid for Products During Contract Term** - The amount SilverSummit Healthplan paid for all drug utilization subject to a manufacturer’s SRA during CY 2021.
 - **Example:** Drug “A” was subject to an SRA from 04/01/2021 to 12/31/2021 would include the amount paid for Drug “A” for claims paid from 04/01/2021 to 12/31/2021.
- **Amount Plan Paid to Pharmacies/Providers for Products Under Contract** – The amount SilverSummit Healthplan paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2021.
- **Total Supplemental Rebates Invoiced** - The supplemental rebate amount invoiced during CY 2021 to manufacturers for drugs subject to SRAs.
- **Total Supplemental Rebates Collected** - The supplemental rebate amount collected during CY 2021 From manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.
 - **Example:** Manufacturer B was invoiced \$100.00 for supplemental rebates in November 2020 and remitted payment in January 2021. This column would include the payment since it was made during CY 2021.
- **Supplemental Rebate Percentage of Drug Spend for Contracted Products** - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

Summary of Supplemental Rebate Agreements during CY 2021	
Number of Contracts	189
Number of Unique Manufacturers Under Contract	183
Amount Plan Paid for Products During Contract Term	\$ 36,717,746
Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term	\$ 36,717,789
Total Supplemental Rebates Invoiced	\$ 1,166,421
Total Supplemental Rebates Collected	\$ 1,104,246
Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products	3.2%

Table 2 below lists the SRAs in place during CY 2021. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity the PBM has contracted with in the SRA.
- Effective Date - The start date of the SRA.
- Term Date - The end date of the SRA.

Table 2

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
60 DEGREES	1/1/2020	12/31/9999
ABBOTT DIABETES CARE	1/1/2020	12/31/2022
ABBVIE INC	1/1/2017	12/31/9999
ACERUS	4/1/2021	12/31/9999
ACORDA THERAPEUTICS INC	1/1/2020	12/31/2023
AERIE	1/1/2020	12/31/2022
AKARX INC	9/1/2020	12/31/9999
AKEBIA THERAPEUTICS INC	1/1/2020	12/31/9999
AKORN, INC	1/1/2020	12/31/2022
ALEXION PHARMACEUTICALS INC	1/1/2020	12/31/9999
ALFASIGMA USA	1/1/2020	12/31/9999
ALK ABELLO INC	1/1/2020	12/31/9999
ALKERMES INC	4/1/2020	12/31/2025
ALLERGAN PHARM	1/1/2020	12/31/9999
ALMATICA	10/1/2020	12/31/9999
ALMIRALL LLC	1/1/2020	12/31/9999
ALVOGEN INC	7/1/2021	12/31/9999
AMAG PHARMACEUTICALS, INC	1/1/2020	12/31/9999
AMARIN	1/1/2020	12/31/9999
AMGEN	1/1/2020	12/31/2022
AMNEAL PHARMACEUTICALS LLC	1/1/2020	12/31/9999
ANI PHARMACEUTICALS	7/1/2021	12/31/9999
ANTARES PHARMA INC	1/1/2020	12/31/9999
ARBOR	1/1/2020	12/31/2022
ARKRAY USA INC	1/1/2020	12/31/2023
ASCEND THERAPEUTICS US, LLC	1/1/2020	12/31/9999
ASCENDIS PHARMA ENDOCRINOLOGY	11/1/2021	12/31/9999
ASCENSIA DIABETES CARE US INC	1/1/2020	12/31/9999
ASEGUA	1/1/2020	12/31/9999
ASSERTIO	1/1/2020	12/31/9999
ASTELLAS PHARMA US	1/1/2020	12/31/9999
ASTRAZENECA	1/1/2020	12/31/9999

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
AVANIR PHARMACEUTICALS	1/1/2020	12/31/2023
AVION PHARMACEUTICALS	1/1/2020	12/31/9999
BANNER LIFE SCIENCES	10/1/2020	12/31/2023
BAUSCH HEALTH US LLC	7/1/2021	6/30/2022
BAUSCH HEALTH US LLC	1/1/2020	12/31/9999
BAYER	1/1/2020	12/31/2022
BIODELIVERY SCIENCES INT	7/1/2019	12/31/9999
BIOGEN	1/1/2020	12/31/9999
BIOHAVEN PHARMACEUTICALS	4/1/2020	12/31/9999
BIOVENTUS LLC	1/1/2020	12/31/9999
BOEHRINGER INGELHEIM	1/1/2020	12/31/9999
BOEHRINGER INGELHEIM	1/1/2020	12/31/9999
BRISTOL-MYERS SQUIBB	1/1/2020	12/31/9999
CELLTRION	10/1/2019	12/31/2022
CEQR CORPORATION	1/1/2021	12/31/9999
CHIESI USA	1/1/2020	12/31/9999
CLARUS THERAPEUTICS	7/1/2021	12/31/9999
CLOVIS ONCOLOGY INC	1/1/2020	12/31/2022
COHERUS BIOSCIENCES	1/1/2020	8/31/2023
COLLEGIUM PHARMACEUTICALS	7/1/2019	12/31/9999
COVIS PHARMA	1/1/2020	12/31/9999
CROWN LABORATORIES	1/1/2020	12/31/2022
CSL BEHRING LLC	1/1/2020	12/31/9999
CUMBERLAND PHARMACEUTICALS	1/1/2020	12/31/9999
CURRAX PHARMACEUTICALS LLC	1/1/2020	12/31/9999
CUTANEA LIFE SCIENCES INC	1/1/2020	12/31/9999
CYCLE PHARMACEUTICALS	1/1/2020	12/31/9999
DERMIRA, INC	1/1/2020	9/30/2022
DEXCOM	1/1/2020	12/31/9999
DIGESTIVE CARE	1/1/2020	12/31/9999
DUCHESNAY USA, INC	1/1/2020	8/31/2022
EGALET CORPORATION	1/1/2020	8/31/2023
EISAI INC	1/1/2020	12/31/9999
ELECTROCORE	1/1/2020	12/31/9999
ELI LILLY & COMPANY	1/1/2020	12/31/2023
EMBECTA CORP	1/1/2020	12/31/9999
EMD SERONO	1/1/2019	6/30/2022
EMERGENT DEVICES	1/1/2021	12/31/9999
ENCORE DERMATOLOGY, INC	1/1/2020	9/30/2021
ENDO PHARMACEUTICAL SOLUTIONS	10/1/2019	12/31/2023

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
EPI HEALTH LLC	1/1/2020	12/31/9999
ESPERION THERAPEUTICS	4/1/2020	12/31/2022
EXELIXIS INC	1/1/2020	12/31/9999
EXELTIS USA DERMATOLOGY	1/1/2020	12/31/9999
EYEVANCE	1/1/2020	12/31/2022
FERRING	1/1/2020	12/31/9999
FIDIA PHARMA USA INC	1/1/2020	12/31/9999
FORTOVIA THERAPEUTICS	1/1/2020	5/31/2022
FORWARD SCIENCE	1/1/2020	12/31/9999
FOUGERA PHARMACEUTICALS INC	1/1/2020	12/31/2021
FRESENIUS USA	1/1/2020	12/31/2022
GALDERMA	1/1/2021	12/31/2023
GALEN	1/1/2020	2/28/2022
GENENTECH	1/1/2020	12/31/2022
GENESIS HEALTH TECHNOLOGIES	1/1/2020	12/31/9999
GILEAD SCIENCES INC	1/1/2020	12/31/9999
GLAXOSMITHKLINE	1/1/2019	12/31/2021
GLAXOSMITHKLINE	1/1/2021	12/31/9999
GLENMARK THERAPEUTICS INC	1/1/2020	12/31/9999
GREENWICH BIOSCIENCES	1/1/2020	12/31/2022
GREER LABORATORIES, INC	1/1/2020	12/31/9999
GRIFOLS USA, LLC	1/1/2020	12/31/9999
HELSINN THERAPEUTICS	1/1/2020	8/31/2021
HIKMA AMERICAS	1/1/2020	12/31/9999
HORIZON MEDICINES LLC	1/1/2020	12/31/9999
HTL-STREFA	4/1/2021	12/31/9999
IMPEL PHARMACEUTICALS	10/1/2021	12/31/9999
INDIVIOR	7/1/2019	12/31/9999
INSMED	7/1/2019	12/31/9999
INSULET	1/1/2020	12/31/9999
INTUITY MEDICAL	10/1/2021	12/31/9999
IPSEN BIOPHARMACEUTICALS INC	1/1/2020	12/31/9999
IRONSHORE	1/1/2020	12/31/9999
JAZZ	4/1/2020	12/31/2022
JOHNSON and JOHNSON	1/1/2017	12/31/2022
JOURNEY MEDICAL	9/1/2020	12/31/9999
KALA PHARMACEUTICALS INC	1/1/2020	12/31/2022
KOWA PHARMACEUTICALS	1/1/2020	12/31/9999
KYOWA KIRIN	1/1/2020	12/31/9999
LEO PHARMA, INC	1/1/2020	12/31/9999

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
LIFESCAN	1/1/2020	12/31/9999
LUPIN PHARMACEUTICALS, INC	7/1/2021	12/31/9999
LUPIN PHARMACEUTICALS, INC	7/1/2013	6/30/2021
MALLINCKRODT	10/1/2019	12/31/9999
MANNKIND CORPORATION	1/1/2020	12/31/9999
MAYNE PHARMA	1/1/2020	12/31/9999
MEDEXUS PHARMA	1/1/2020	12/31/9999
MELINTA THERAPEUTICS LLC	1/1/2020	12/31/9999
MERCK & CO, INC	1/1/2020	12/31/9999
METUCHEN	1/1/2020	12/31/9999
MILLENNIUM PHARMACEUTICALS	1/1/2021	12/31/2023
MILLICENT	1/1/2020	12/31/9999
MINIMED DISTRIBUTION CORP	1/1/2020	12/31/9999
MISSION	1/1/2020	12/31/9999
MYLAN PHARMACEUTICALS INC	1/1/2020	12/31/2022
NABRIVA	1/1/2020	12/31/9999
NEOS THERAPEUTICS LP	1/1/2020	12/31/2022
NESTLE HEALTH SCIENCE	1/1/2021	12/31/9999
NEURELIS	10/1/2020	12/31/9999
NEUROCRINE BIOSCIENCES INC	1/1/2020	12/31/9999
NODEN PHARMA USA	1/1/2020	12/31/9999
NOVARTIS	1/1/2020	12/31/9999
NOVEN THERAPEUTICS LLC	1/1/2020	12/31/9999
NOVO NORDISK	1/1/2020	12/31/9999
NOVO NORDISK	3/1/2020	12/31/9999
OCTAPHARMA USA	7/1/2021	12/31/9999
OPKO PHARMACEUTICALS LLC	1/1/2020	12/31/9999
OPTINOSE US, INC	1/1/2020	12/31/9999
OREXO	7/1/2019	12/31/9999
ORTHOGENRX	1/1/2020	7/31/2023
OTSUKA	1/1/2020	12/31/9999
PADAGIS US LLC	1/1/2020	12/31/9999
PARATEK PHARMACEUTICALS, INC	1/1/2020	12/31/2022
PARI RESPIRATORY	1/1/2020	12/31/9999
PFIZER US PHARM	1/1/2020	12/31/9999
PHARMING HEALTHCARE INC	1/1/2020	12/31/9999
PIERRE FABRE PHARMA INC	1/1/2020	12/31/9999
PURDUE PHARMA	10/1/2019	12/31/9999
RADIUS HEALTH INC	1/1/2020	12/31/9999
RB HEALTH (US) LLC	1/1/2020	12/31/9999

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
REDHILL BIOPHARMA	1/1/2020	12/31/2023
REGENERON PHARMACEUTICALS INC	10/1/2020	12/31/9999
RESILIA PHARMACEUTICALS	10/1/2021	12/31/9999
ROCHE DIAGNOSTICS	1/1/2020	12/31/2022
SANDOZ INC	4/1/2020	12/31/9999
SANOFI - AVENTIS	7/1/2013	12/31/9999
SCILEX PHARMACEUTICALS INC	7/1/2019	12/31/9999
SEBELA PHARMACEUTICALS INC	1/1/2021	12/31/9999
SECURA BIO	1/1/2021	12/31/9999
SHIONOGI & COMPANY, INC	1/1/2020	12/31/9999
SK LIFE SCIENCE	4/1/2020	12/31/9999
SOBI INC	1/1/2020	12/31/2024
SUN PHARMA INDUSTRIES INC	1/1/2019	12/31/2023
SUN PHARMA INDUSTRIES INC	1/1/2020	12/31/9999
SUNOVION	1/1/2020	12/31/2022
SUPERNUS PHARMACEUTICALS, INC	1/1/2020	12/31/9999
TAKEDA	10/1/2019	12/31/9999
TERSERA THERAPEUTICS	1/1/2020	12/31/9999
TEVA	1/1/2020	12/31/9999
THERAPEUTICSMD INC	1/1/2020	12/31/9999
TOLMAR PHARMACEUTICALS INC	10/1/2020	12/31/9999
TRAVERE THERAPEUTICS INC	1/1/2020	12/31/9999
TRIS PHARMA	1/1/2020	12/31/9999
TRIVIDIA HEALTH	1/1/2020	12/31/9999
UCB INC	1/1/2020	9/30/2022
UPSHER-SMITH	1/1/2020	12/31/9999
UROVANT	8/1/2021	12/31/9999
VELOXIS PHARMACEUTICALS	1/1/2020	12/31/9999
VERTICAL PHARMACEUTICALS	1/1/2020	12/31/9999
VIFOR PHARMA, INC	1/1/2020	12/31/2022
VIVUS	1/1/2020	12/31/9999
VYERA PHARMACEUTICALS	1/1/2020	12/31/9999
VYNE PHARMACEUTICALS INC	1/1/2021	2/28/2023
WOMENS CHOICE PHARMACEUTICALS	1/1/2020	12/31/9999
XERIS	3/1/2020	12/31/9999
ZEALAND PHARMA US INC	1/1/2020	12/31/9999
ZIMMER US, INC	1/1/2020	12/31/2022

Table 3 below provides the value for each individual SRA. Table 3 is sorted by descending contract value.

Table 3 Column Definitions:

- Manufacturer Name - The name of the entity the PBM has contracted within the SRA.
- Amount Plan Paid for Products During Contract Term - The amount paid for all drugs subject to a manufacturer’s SRA during CY 2021.
 - Example: Drug “A” was subject to an SRA from 06/01/2019 to 03/31/2021. This column would include the amount paid for Drug “A” for claims paid from 01/01/2021 to 03/31/2021.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2021 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.

Table 3

Supplemental Rebate Agreements during CY 2021				
Manufacturer	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
Manufacturer 1	\$3,195,023.83	\$3,195,023.83	\$311,866.33	\$311,700.16
Manufacturer 2	\$191,250.58	\$191,250.58	\$146,544.28	\$94,932.47
Manufacturer 3	\$1,082,924.86	\$1,082,924.86	\$145,414.68	\$145,161.33
Manufacturer 4	\$3,099,176.24	\$3,099,176.24	\$112,417.48	\$107,605.83
Manufacturer 5	\$2,414,070.14	\$2,414,070.14	\$92,790.30	\$91,851.71
Manufacturer 6	\$1,325,600.73	\$1,325,600.73	\$87,843.04	\$87,842.60
Manufacturer 7	\$703,532.80	\$703,532.80	\$58,216.86	\$57,936.90
Manufacturer 8	\$247,200.00	\$247,200.00	\$40,000.46	\$40,000.46
Manufacturer 9	\$133,601.12	\$133,601.12	\$27,391.82	\$24,114.84
Manufacturer 10	\$77,242.08	\$77,242.08	\$25,888.72	\$26,209.92
Manufacturer 11	\$46,033.77	\$46,033.77	\$16,917.90	\$16,917.90
Manufacturer 12	\$630,458.68	\$630,458.68	\$16,542.08	\$16,541.39
Manufacturer 13	\$1,929,320.08	\$1,929,320.08	\$11,940.11	\$11,940.07
Manufacturer 14	\$154,780.52	\$154,780.52	\$11,432.21	\$10,704.94
Manufacturer 15	\$1,302,156.08	\$1,302,156.08	\$8,913.38	\$8,913.38
Manufacturer 16	\$638,613.03	\$638,647.35	\$8,692.53	\$8,689.03
Manufacturer 17	\$143,713.14	\$143,713.14	\$6,824.25	\$6,824.25
Manufacturer 18	\$488,926.43	\$488,926.43	\$6,670.53	\$6,670.53
Manufacturer 19	\$476,698.08	\$476,698.08	\$4,590.04	\$3,146.20
Manufacturer 20	\$419,210.48	\$419,212.97	\$4,533.70	\$4,417.53
Manufacturer 21	\$48,313.34	\$48,313.34	\$4,522.50	\$4,522.50
Manufacturer 22	\$20,358.85	\$20,358.85	\$4,292.83	\$4,092.39
Manufacturer 23	\$117,378.87	\$117,378.87	\$3,564.56	\$3,564.56
Manufacturer 24	\$13,328.87	\$13,328.87	\$2,172.34	\$2,172.34
Manufacturer 25	\$26,374.30	\$26,374.30	\$1,507.09	\$1,507.09
Manufacturer 26	\$22,099.83	\$22,099.83	\$1,246.49	\$1,246.49
Manufacturer 27	\$18,174.68	\$18,174.68	\$1,177.38	\$1,177.38

Manufacturer 28	\$13,577.76	\$13,577.76	\$863.42	\$863.42
Manufacturer 29	\$7,624.12	\$7,624.12	\$517.84	-
Manufacturer 30	\$21,313.58	\$21,313.58	\$356.51	\$457.95
Manufacturer 31	\$4,543.42	\$4,543.42	\$335.32	\$335.32
Manufacturer 32	\$1,444,435.09	\$1,444,435.09	\$252.11	\$1,697.81
Manufacturer 33	\$2,021.77	\$2,021.77	\$120.74	\$110.84
Manufacturer 34	\$405.86	\$405.86	\$113.41	\$113.41
Manufacturer 35	\$332.84	\$332.84	\$74.15	\$74.15
Manufacturer 36	\$439.68	\$439.68	\$13.23	\$13.23
Manufacturer 37	\$479.68	\$479.68	\$11.62	\$11.62
Manufacturer 38	\$45.96	\$47.04	\$2.12	\$2.12
Manufacturer 39	\$1,910.97	\$1,910.97	(36.55)	\$278.73
Manufacturer 40	\$1,247,475.93	\$1,247,475.93	(117.23)	(117.23)
Manufacturer 41	\$6,664,732.64	\$6,664,732.64	-	-
Manufacturer 42	\$1,262,544.10	\$1,262,544.10	-	-
Manufacturer 43	\$1,050,368.57	\$1,050,368.57	-	-
Manufacturer 44	\$1,022,508.59	\$1,022,508.59	-	-
Manufacturer 45	\$544,198.64	\$544,198.64	-	-
Manufacturer 46	\$487,727.84	\$487,727.84	-	-
Manufacturer 47	\$372,219.55	\$372,219.55	-	-
Manufacturer 48	\$327,552.57	\$327,552.57	-	-
Manufacturer 49	\$309,855.76	\$309,855.76	-	-
Manufacturer 50	\$256,438.37	\$256,438.37	-	-
Manufacturer 51	\$241,913.43	\$241,913.43	-	-
Manufacturer 52	\$209,340.01	\$209,340.01	-	-
Manufacturer 53	\$180,195.04	\$180,195.79	-	-
Manufacturer 54	\$144,371.40	\$144,371.40	-	-
Manufacturer 55	\$142,324.74	\$142,324.74	-	-
Manufacturer 56	\$137,663.95	\$137,663.95	-	-
Manufacturer 57	\$126,347.39	\$126,347.39	-	-
Manufacturer 58	\$124,061.60	\$124,061.60	-	-
Manufacturer 59	\$120,983.50	\$120,983.50	-	-
Manufacturer 60	\$106,352.09	\$106,352.09	-	-
Manufacturer 61	\$74,517.15	\$74,517.15	-	-
Manufacturer 62	\$69,801.80	\$69,801.80	-	-
Manufacturer 63	\$65,122.86	\$65,122.86	-	-
Manufacturer 64	\$63,000.85	\$63,000.85	-	-
Manufacturer 65	\$62,882.77	\$62,882.77	-	-
Manufacturer 66	\$62,298.99	\$62,298.99	-	-
Manufacturer 67	\$60,782.51	\$60,782.51	-	-
Manufacturer 68	\$52,222.93	\$52,222.93	-	-
Manufacturer 69	\$49,412.33	\$49,412.33	-	-
Manufacturer 70	\$47,882.11	\$47,882.11	-	-
Manufacturer 71	\$44,467.12	\$44,467.12	-	-
Manufacturer 72	\$44,197.92	\$44,197.92	-	-
Manufacturer 73	\$41,447.74	\$41,447.74	-	-
Manufacturer 74	\$40,927.89	\$40,927.89	-	-
Manufacturer 75	\$35,982.49	\$35,982.49	-	-
Manufacturer 76	\$33,736.20	\$33,736.20	-	-
Manufacturer 77	\$33,476.77	\$33,480.93	-	-
Manufacturer 78	\$30,459.91	\$30,459.91	-	-
Manufacturer 79	\$27,697.05	\$27,697.05	-	-
Manufacturer 80	\$26,589.07	\$26,589.07	-	-
Manufacturer 81	\$24,619.40	\$24,619.40	-	-
Manufacturer 82	\$17,437.30	\$17,437.30	-	-
Manufacturer 83	\$14,813.80	\$14,813.80	-	-
Manufacturer 84	\$13,750.09	\$13,750.09	-	-

Manufacturer 85	\$10,950.00	\$10,950.00	-	-
Manufacturer 86	\$10,323.57	\$10,323.57	-	-
Manufacturer 87	\$9,930.36	\$9,930.36	-	-
Manufacturer 88	\$9,626.27	\$9,626.27	-	-
Manufacturer 89	\$9,158.19	\$9,158.19	-	-
Manufacturer 90	\$8,236.80	\$8,236.80	-	-
Manufacturer 91	\$6,543.02	\$6,543.02	-	-
Manufacturer 92	\$6,375.45	\$6,375.45	-	-
Manufacturer 93	\$6,133.68	\$6,133.68	-	-
Manufacturer 94	\$5,817.78	\$5,817.78	-	-
Manufacturer 95	\$5,402.00	\$5,402.00	-	-
Manufacturer 96	\$5,040.26	\$5,040.26	-	-
Manufacturer 97	\$4,715.89	\$4,715.89	-	-
Manufacturer 98	\$4,246.96	\$4,246.96	-	-
Manufacturer 99	\$3,919.73	\$3,919.73	-	-
Manufacturer 100	\$3,210.51	\$3,210.51	-	-
Manufacturer 101	\$3,084.20	\$3,084.20	-	-
Manufacturer 102	\$2,536.07	\$2,536.07	-	-
Manufacturer 103	\$2,411.84	\$2,411.84	-	-
Manufacturer 104	\$2,359.29	\$2,359.29	-	-
Manufacturer 105	\$2,310.81	\$2,310.81	-	-
Manufacturer 106	\$2,159.70	\$2,159.70	-	-
Manufacturer 107	\$2,060.21	\$2,060.21	-	-
Manufacturer 108	\$1,892.58	\$1,892.58	-	-
Manufacturer 109	\$1,763.77	\$1,763.77	-	-
Manufacturer 110	\$1,456.64	\$1,456.64	-	-
Manufacturer 111	\$1,396.90	\$1,396.90	-	-
Manufacturer 112	\$1,343.22	\$1,343.22	-	-
Manufacturer 113	\$988.46	\$988.46	-	-
Manufacturer 114	\$791.77	\$791.77	-	-
Manufacturer 115	\$675.96	\$675.96	-	-
Manufacturer 116	\$577.97	\$577.97	-	-
Manufacturer 117	\$553.90	\$553.90	-	-
Manufacturer 118	\$182.75	\$182.75	-	-
Manufacturer 119	\$113.14	\$113.14	-	-
Manufacturer 120	\$23.78	\$23.78	-	-
Manufacturer 121	\$23.01	\$23.01	-	-
Manufacturer 122	\$14.85	\$14.85	-	-
Manufacturer 123	-	-	-	-
Manufacturer 124	-	-	-	-
Manufacturer 125	-	-	-	-
Manufacturer 126	-	-	-	-
Manufacturer 127	-	-	-	-
Manufacturer 128	-	-	-	-
Manufacturer 129	-	-	-	-
Manufacturer 130	-	-	-	-
Manufacturer 131	-	-	-	-
Manufacturer 132	-	-	-	-
Manufacturer 133	-	-	-	-
Manufacturer 134	-	-	-	-
Manufacturer 135	-	-	-	-
Manufacturer 136	-	-	-	-
Manufacturer 137	-	-	-	-
Manufacturer 138	-	-	-	-
Manufacturer 139	-	-	-	-
Manufacturer 140	-	-	-	-
Manufacturer 141	-	-	-	-

Manufacturer 142	-	-	-	-
Manufacturer 143	-	-	-	-
Manufacturer 144	-	-	-	-
Manufacturer 145	-	-	-	-
Manufacturer 145	-	-	-	-
Manufacturer 147	-	-	-	-
Manufacturer 148	-	-	-	-
Manufacturer 149	-	-	-	-
Manufacturer 150	-	-	-	-
Manufacturer 151	-	-	-	-
Manufacturer 152	-	-	-	-
Manufacturer 153	-	-	-	-
Manufacturer 154	-	-	-	-
Manufacturer 155	-	-	-	-
Manufacturer 156	-	-	-	-
Manufacturer 157	-	-	-	-
Manufacturer 158	-	-	-	-
Manufacturer 159	-	-	-	-
Manufacturer 160	-	-	-	-
Manufacturer 161	-	-	-	-
Manufacturer 162	-	-	-	-
Manufacturer 163	-	-	-	-
Manufacturer 164	-	-	-	-
Manufacturer 165	-	-	-	-
Manufacturer 166	-	-	-	-
Manufacturer 167	-	-	-	-
Manufacturer 168	-	-	-	-
Manufacturer 169	-	-	-	-
Manufacturer 170	-	-	-	-
Manufacturer 171	-	-	-	-
Manufacturer 172	-	-	-	-
Manufacturer 173	-	-	-	-
Manufacturer 174	-	-	-	-
Manufacturer 175	-	-	-	-
Manufacturer 176	-	-	-	-
Manufacturer 177	-	-	-	-
Manufacturer 178	-	-	-	-
Manufacturer 179	-	-	-	-
Manufacturer 180	-	-	-	-
Manufacturer 181	-	-	-	-
Manufacturer 182	-	-	-	-
Manufacturer 183	-	-	-	-

The next two tables provide additional information as required by Senate Bill 378 (2019). Table 4 below provides the values and total amounts of dispensing fees paid by SilverSummit Healthplan and its PBM to pharmacies.

Table 4 Column Definitions:

- Retail 30 Days – Dispensing fee cost for 0–60-day supplies at a retail location
- Retail 90-100 Days – Dispensing fee cost for 90–100-day supplies at a retail location
- Mail Order – Dispensing fee cost for mail order pharmacies
- Specialty – Dispensing fees cost for specialty pharmacies

Table 4

Dispensing Fees during CY 2021				
Type of Dispensing Fee:	Retail 30 Days	Retail 90-100 Days	Mail Order	Specialty
Dispensing Fee	\$0.06	\$0.04	\$0.00	\$0.02
Totals	\$58,035	\$1,430	\$0.00	\$423
Grand Total	\$59,888			

Table 5 below provides a summary of measures employed by the pharmacy benefit manager contracted by SilverSummit Healthplan to control outpatient prescription drug costs.

Table 5 Row Definitions:

- Utilization Management – Measures to control use of pharmacy services for medical necessity and appropriateness to provide efficacious and cost-effective medications. Examples of utilization management include but not limited to prior authorization, step therapy, and quantity limits.
- Prior Authorization – Is a prospective review for an approval for the use of a medication.
- Step Therapy – Is a utilization management program that requires a patient to try a lower cost medication before stepping up to a similar-acting more expensive medication.
- Quantity limits – Limits medication use to the maximum dose of a medication.
- Pharmacy Networks – Is a group of pharmacies contracted with the payer where patients can fill medications.
- Preferred Drug List – Is a list of preferred medications that requires a patient to try the preferred medication before using a non-preferred medication.
- Prospective Drug Utilization Review (ProDUR) Activities – ProDUR activities are automated, structured, ongoing review of prescribing, dispensing and use of medications.

Table 5

Measures to Control Costs during CY 2021		
Utilization Management	Prior Authorization	Yes
	Step Therapy	Yes
	Quantity Limits	Yes
Pharmacy Networks		Yes
Preferred Drug List		Yes
ProDUR Activities		Yes

Nevada Medicaid Fee-For-Service Supplemental Rebate Agreement Report Calendar Year 2021

The overall drug rebate process follows the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) as codified in Section 1927 of the Social Security Act (42 U.S.C. 1396r-8) and regulations promulgated by the Centers for Medicare & Medicaid Services (CMS). Under the Medicaid Drug Rebate Program (MDRP), drug manufacturers must provide rebates to the federal government and states as a condition of having their drugs covered by Medicaid. The MDRP helps lower Medicaid prescription drug spending by ensuring that state Medicaid agencies receive discounts in the form of rebates on covered outpatient drugs. In order for their covered outpatient drugs to be covered and reimbursed by state Medicaid agencies, pharmaceutical manufacturers enter into and have in effect the National Drug Rebate Agreement (NDRA) with the Secretary of the United States Department of Health and Human Services (HHS). The NDRA provides for the payment of Federal rebates by pharmaceutical manufacturers. Nevada Medicaid and the other state Medicaid Programs are third party beneficiaries of the NDRA. The formulas for calculating the Federal Unit Rebate amount (URA) are set out by Federal statute.

States may also directly negotiate with manufacturers for voluntary supplemental rebates on top of federally required rebates. States may enter into separate or supplemental drug rebate agreements as long as such agreements achieve drug rebates equal to or greater than the drug rebates set forth in the Secretary's national rebate agreement with drug manufacturers, which is published at 56 F.R. 7049 (1991).

The supplemental rebate does not reduce what is being paid under the NDRA but instead, provides an additional tool for states to help manage prescription drug spend. Pharmaceutical manufacturers enter into supplemental rebate agreements (SRA) with state Medicaid agencies to ensure preferred status on the states' Preferred Drug Lists (PDL).

The Nevada Medicaid Supplemental Drug Rebate Program (NMSDRP) has been in effect since January 1, 2012. The SRAs are between the manufacturers and the Nevada Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP). Generally, the SRAs are in effect for one calendar year beginning on January 1st and terminating on December 31st. In some instances, the SRA can have an alternative start date as a result of either newly contracted drugs or new National Drug Codes released for drugs currently under contract. Additionally, there are factors that may cause a contract to have a non-December 31st end date such as a product moving to non-preferred status or to coincide with planned Silver State Scripts Board (SSSB) review.

During Calendar Year 2021, the rebates negotiated under the NMSDRP only applied to Medicaid fee-for-service (FFS) utilization. The other entities, authorized under Senate Bill 378 (2019) to participate in the Medicaid FFS PDL, did not elect to participate.

Supplemental rebates are calculated based upon two different types of calculations at the unit level:

- "Percentage of WAC" - set percentage of the drug's published wholesale acquisition cost (WAC).
- "GNUP" (Guaranteed Net Unit Price) - WAC minus the Federal URA minus the GNUP.
 - In the event a drug's WAC minus the Federal URA is lower than the GNUP, the supplemental rebate rate is zero.
 - Even though there are instances when the GNUP contract does not produce supplemental rebate savings, they remain in place to give Nevada Medicaid price protection in case the manufacturer raises the drug price during the contract term.

The type of calculation used for a particular product is defined within a manufacturer’s SRA with the Nevada Department of Health and Human Services, DHCFP.

Section F of the SRA provides confidentiality assurance that the State and the manufacturer agree to maintain confidentiality and to not disclose pricing information or pricing related terms and conditions.

The Nevada Department of Health and Human Services, DHCFP had 38 SRAs in place that were in effect during Calendar Year 2021 (January 1, 2021 – December 31, 2021) (hereinafter referred to as CY 2021). Table 1 below summarizes the agreements.

Table 1 Row Definitions:

- **Number of Contracts** - The count of signed SRAs that were in force during some period within CY 2021.
- **Number of Unique Manufacturers Under Contract** - The count of unique manufacturers with a signed SRA in force during some period within CY 2021.
- **Amount Plan Paid for Products During Contract Term** - The amount The Nevada Department of Health and Human Services, DHCFP paid for all drug utilization subject to a manufacturer’s SRA during CY 2021.
 - **Example:** Drug “A” was subject to an SRA from 04/01/2021 to 12/31/2021 would include the amount paid for Drug “A” for claims paid from 04/01/2021 to 12/31/2021.
- **Amount Medicaid Paid to Pharmacies/Providers for Products Under Contract** – The amount Medicaid paid to pharmacies and providers for drugs subject to a manufacturer’s SRA during CY 2021.
- **Total Supplemental Rebates Invoiced** - The supplemental rebate amount invoiced during CY 2021 to manufacturers for drugs subject to SRAs.
- **Total Supplemental Rebates Collected** - The supplemental rebate amount collected during CY 2021 From manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.
 - **Example:** Manufacturer B was invoiced \$100.00 for supplemental rebates in November 2020 and remitted payment in January 2021. This column would include the payment since it was made during CY 2021.
- **Supplemental Rebate Percentage of Drug Spend for Contracted Products** - The result of dividing the contract value by the drug spend for contracted drugs, expressed as a percentage.

Table 1

Summary of Supplemental Rebate Agreements during CY 2021	
Number of Contracts	38
Number of Unique Manufacturers Under Contract	32
Amount Plan Paid for Products During Contract Term	\$76,530,431.22
Amount Plan Paid to Pharmacies/Providers for Products Under Contract During Contract Term	\$76,530,431.22
Total Supplemental Rebates Invoiced	\$10,883,847.34
Total Supplemental Rebates Collected	\$9,116,888.34
Supplemental Rebate Percentage of the Total the Plan Paid for Contracted Products	14.2%

Table 2 below lists the SRAs in place during CY 2021. The list is sorted alphabetically by manufacturer name and by SRA start dates.

Table 2 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted with in the SRA.
- Effective Date - The start date of the SRA.
- Term Date - The end date of the SRA.

Table 2

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
ABBVIE US LLC	01/01/2021	12/31/2021
AERIE PHARMACEUTICALS, INC.	01/01/2021	12/31/2021
ALKERMES, INC.	01/01/2021	12/31/2021
ALLERGAN USA, INC.	01/01/2021	12/31/2021
ALLERGAN USA, INC.	04/01/2021	12/31/2021
AMGEN USA, INC.	01/01/2021	12/31/2021
AMGEN USA, INC.	11/01/2021	12/31/2021
ASEGUA THERAPEUTICS, LLC	01/01/2021	12/31/2021
ASTRAZENECA PHARMACEUTICALS LP	01/01/2021	12/31/2021
BAYER HEALTHCARE, LLC	01/01/2021	12/31/2021
BIOGEN IDEC U.S. CORPORATION	01/01/2021	12/31/2021
BIOHAVEN PHARMACEUTICALS, INC.	04/01/2021	12/31/2021
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	01/01/2021	12/31/2021
BRISTOL-MYERS SQUIBB COMPANY	01/01/2021	12/31/2021
CHIESI USA, INC.	01/01/2021	12/31/2021
DUCHESNAY USA	01/01/2021	12/31/2021
EISAI INC	01/01/2021	12/31/2021
ELI LILLY AND COMPANY	09/01/2020	03/31/2021
ELI LILLY AND COMPANY	01/01/2021	12/31/2021
ELI LILLY AND COMPANY	04/01/2021	12/31/2021
GENZYME CORPORATION	01/01/2021	12/31/2021
GILEAD SCIENCES, INC.	01/01/2021	12/31/2021
INDIVIOR INC.	01/01/2021	12/31/2021
JANSSEN PHARMACEUTICALS, INC.	01/01/2021	12/31/2021
NESTLE HEALTHCARE	05/01/2021	12/31/2021
NOVARTIS PHARMACEUTICALS CORPORATION	01/01/2021	12/31/2021
NOVO NORDISK INC.	01/01/2021	12/31/2021
OTSUKA AMERICA PHARMACEUTICAL, INC.	01/01/2021	12/31/2021
PARAPRO, LLC	01/01/2021	12/31/2021
PARI RESPIRATORY EQUIPMENT, INC.	01/01/2021	12/31/2021
PFIZER INC	01/01/2021	12/31/2021

Supplemental Rebate Agreements during CY 2021		
Manufacturer Name	Effective Date	Term Date
SANOFI-AVENTIS US LLC	01/01/2021	12/31/2021
SUNOVION PHARMACEUTICALS INC.	01/01/2021	12/31/2021
TAKEDA PHARMACEUTICALS AMERICA, INC.	01/01/2021	12/31/2021
TEVA PHARMACEUTICALS	06/01/2020	03/31/2021
TEVA PHARMACEUTICALS	01/01/2021	12/31/2021
TEVA PHARMACEUTICALS	04/01/2021	12/31/2021
UCB, INC.	01/01/2021	12/31/2021

Table 3 below provides the value for each individual SRA. Table 3 is sorted by descending contract value.

Table 3 Column Definitions:

- Manufacturer Name - The name of the entity the State has contracted within the SRA.
- Amount Plan Paid for Products During Contract Term - The amount paid for all drugs subject to a manufacturer's SRA during CY 2021.
 - Example: Drug "A" was subject to an SRA from 06/01/2019 to 03/31/2021. This column would include the amount paid for Drug "A" for claims paid from 01/01/2021 to 03/31/2021.
- Amount Plan Paid to Pharmacies/Providers for Products Under Contract - The amount paid to pharmacies and providers for drugs subject to a manufacturer's SRA during CY 2021.
- Total Supplemental Rebates Invoiced - The supplemental rebate amount invoiced during CY 2021 to manufacturers for drugs subject to SRAs.
- Total Supplemental Rebates Collected - The supplemental rebate amount collected during CY 2021 from manufacturers for drugs subject to SRAs regardless of when the rebate liability was incurred.

Table 3

Supplemental Rebate Agreements during CY 2021				
Manufacturer Name	Amount Plan Paid for Products During Contract Term	Amount Plan Paid to Pharmacies/ Providers for Products Under Contract During Contract Term	Total Supplemental Rebates Invoiced	Total Supplemental Rebates Collected
ABBVIE US LLC	\$11,485,964.14	\$11,485,964.14	\$5,722,015.35	\$3,955,980.11
ELI LILLY AND COMPANY	\$6,007,232.79	\$6,007,232.79	\$1,294,596.98	\$1,072,613.93
PFIZER INC	\$3,370,792.91	\$3,370,792.91	\$739,834.51	\$728,391.09
NOVO NORDISK INC.	\$3,133,224.16	\$3,133,224.16	\$486,847.84	\$636,122.38
OTSUKA AMERICA PHARMACEUTICAL, INC.	\$6,516,530.36	\$6,516,530.36	\$465,692.97	\$441,768.09
JANSSEN PHARMACEUTICALS, INC.	\$10,143,802.91	\$10,143,802.91	\$378,321.05	\$310,204.51
INDIVIOR INC.	\$1,962,007.79	\$1,962,007.79	\$349,590.50	\$318,062.39
SUNOVION PHARMACEUTICALS INC.	\$7,866,268.44	\$7,866,268.44	\$266,542.39	\$310,570.59
ALLERGAN USA, INC.	\$5,029,767.00	\$5,029,767.00	\$259,167.56	\$254,847.89
BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.	\$1,263,106.33	\$1,263,106.33	\$159,133.33	\$221,808.89

UCB, INC.	\$4,948,968.38	\$4,948,968.38	\$126,752.24	\$54,179.92
ALKERMES, INC.	\$1,042,472.24	\$1,042,472.24	\$108,554.51	\$238,974.22
ASEGUA THERAPEUTICS, LLC	\$633,609.07	\$633,609.07	\$91,056.47	\$90,097.96
SANOFI-AVENTIS US LLC	\$1,466,864.74	\$1,466,864.74	\$74,257.99	\$33,943.28
NOVARTIS PHARMACEUTICALS CORPORATION	\$630,938.69	\$630,938.69	\$63,591.38	\$152,093.99
TAKEDA PHARMACEUTICALS AMERICA, INC.	\$1,628,339.24	\$1,628,339.24	\$52,847.25	\$56,947.54
AMGEN USA, INC.	\$3,063,709.00	\$3,063,709.00	\$44,174.88	\$35,753.40
GILEAD SCIENCES, INC.	\$759,431.86	\$759,431.86	\$42,414.29	\$69,807.94
ASTRAZENECA PHARMACEUTICALS LP	\$424,438.60	\$424,438.60	\$41,696.82	\$42,257.16
BIOGEN IDEC U.S. CORPORATION	\$1,195,032.21	\$1,195,032.21	\$35,011.37	\$17,379.43
EISAI INC	\$303,052.84	\$303,052.84	\$33,494.86	\$34,540.54
AERIE PHARMACEUTICALS, INC.	\$70,330.05	\$70,330.05	\$18,589.76	\$18,674.38
NESTLE HEALTHCARE	\$164,882.16	\$164,882.16	\$12,788.66	\$0.00
BIOHAVEN PHARMACEUTICALS, INC.	\$383,872.65	\$383,872.65	\$7,010.36	\$0.00
TEVA PHARMACEUTICALS	\$60,149.05	\$60,149.05	\$2,667.75	\$18,252.48
BRISTOL-MYERS SQUIBB COMPANY	\$2,963,326.68	\$2,963,326.68	\$2,607.25	\$0.00
CHIESI USA, INC.	\$2,030.10	\$2,030.10	\$2,474.30	\$2,474.30
DUCHESNAY USA	\$9,463.13	\$9,463.13	\$1,847.55	\$555.48
PARAPRO, LLC	\$823.70	\$823.70	\$267.17	\$243.61
BAYER HEALTHCARE, LLC	\$0.00	\$0.00	\$0.00	\$0.00
GENZYME CORPORATION	\$0.00	\$0.00	\$0.00	\$239.55
PARI RESPIRATORY EQUIPMENT, INC.	\$0.00	\$0.00	\$0.00	\$103.29

In addition to the collections listed in Table 3, during CY 2021 the State received \$22,285.98 in supplemental rebate payments from manufacturers without an active SRA in CY 2021. These payments are the result of supplemental rebate liabilities incurred by the manufacturer prior to CY 2021.

The next two tables provide additional information as required by Senate Bill 378 (2019). Table 4 below provides the values and total amounts of dispensing fees paid by DHCFP to pharmacies.

Table 4 Column Definitions:

- Retail 30 Days – Dispensing fee cost for 0–60-day supplies at a retail location
- Retail 60-100 Days – Dispensing fee cost for 60–100-day supplies at a retail location
- Mail Order – Dispensing fee cost for mail order pharmacies
- Specialty – Dispensing fees cost for specialty pharmacies

Table 4

Dispensing Fees during CY 2021				
Type of Dispensing Fee:	Retail 30 Days	Retail 60-100 Days	Mail Order	Specialty
Dispensing Fee	\$10.17	\$10.17	\$10.17	\$10.17
Totals	\$15,299,290.24	\$3,146,722.61	\$2,461.56	\$325,608.95
Grand Total	\$18,774,083.36			

Table 5 below provides a summary of measures employed by the pharmacy benefit manager contracted by DHCFP to control outpatient prescription drug costs.

Table 5 Row Definitions:

- Utilization Management – Measures to control use of pharmacy services for medical necessity and appropriateness to provide efficacious and cost-effective medications. Examples of utilization management include but not limited to prior authorization, step therapy, and quantity limits.
- Prior Authorization – Is a prospective review for an approval for the use of a medication.
- Step Therapy – Is a utilization management program that requires a patient to try a lower cost medication before stepping up to a similar-acting more expensive medication.
- Quantity limits – Limits medication use to the maximum dose of a medication.
- Pharmacy Networks – Is a group of pharmacies contracted with the payer where patients can fill medications.
- Preferred Drug List – Is a list of preferred medications that requires a patient to try the preferred medication before using a non-preferred medication.
- Prospective Drug Utilization Review (ProDUR) Activities – ProDUR activities are automated, structured, ongoing review of prescribing, dispensing and use of medications.

Table 5

Measures to Control Costs during CY 2021		
Utilization Management	Prior Authorization	Yes
	Step Therapy	No
	Quantity Limits	Yes
Pharmacy Networks		No
Preferred Drug List		Yes
ProDUR Activities		Yes